Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Drug Investigation
Erschienen in: Clinical Drug Investigation 5/2017

01.05.2017 | Original Research Article

Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective

verfasst von: Alessia Pepe, Giuseppe Rossi, Anthony Bentley, Maria Caterina Putti, Ludovica Frizziero, Domenico Giuseppe D’Ascola, Liana Cuccia, Anna Spasiano, Aldo Filosa, Vincenzo Caruso, Aishah Hanif, Antonella Meloni

Erschienen in: Clinical Drug Investigation | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Deferiprone (DFP), deferasirox (DFX) and deferoxamine (DFO) are used in thalassaemia major (TM) patients to treat chronic iron overload. We evaluated the cost-effectiveness of DFP, compared with DFX and DFO monotherapy, from an Italian healthcare system perspective.

Methods

A Markov model was used over a time horizon of 5 years. Italian-specific cost data were combined with Italian efficacy data. Costs and quality-adjusted life years (QALYs) were calculated for each treatment, with cost-effectiveness expressed as cost per QALY.

Results

In all scenarios modelled, DFP was the dominant treatment strategy. Sensitivity analyses showed that DFP dominated the other treatments with a >99% likelihood of being cost-effective against DFX and DFO at a willingness to pay threshold of €20,000 per QALY.

Conclusions

DFP was the dominant and most cost-effective treatment for managing chronic iron overload in TM patients. Its use can result in substantial cost savings for the Italian healthcare system.
Literatur
1.
2.
3.
Angelucci E, Barosi G, Camaschella C, Cappellini MD, Cazzola M, Galanello R, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008;93(5):741–52.CrossRefPubMed
4.
Carbone S. Thalassemia in Messina: a sociological approach to chronic disease. Thalass Rep. 2014;4(1):2207.
5.
6.
7.
McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol Assess. 2009;13(1):iii–iv, ix–xi, 1–121.
8.
Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–93.PubMed
9.
Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. Blood. 2004;104(1):34–9.CrossRefPubMed
10.
Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051–2.CrossRefPubMed
11.
Pepe A, Meloni A, Rossi G, Caruso V, Cuccia L, Spasiano A, et al. Cardiac complications and diabetes in thalassaemia major: a large historical multicentre study. Br J Haematol. 2013;163(4):520–7.CrossRefPubMed
12.
Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2(8653):27–30.CrossRefPubMed
13.
14.
Abetz L, Baladi JF, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes. 2006;4:73.CrossRefPubMedPubMedCentral
15.
Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919–29.CrossRefPubMed
16.
Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733–7.CrossRefPubMed
17.
Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10(1):42.CrossRefPubMedPubMedCentral
18.
19.
Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961–8.CrossRefPubMedPubMedCentral
20.
Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson. 2009;11(1):20.CrossRefPubMedPubMedCentral
21.
Maggio A, D’Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002;28(2):196–208.CrossRefPubMed
22.
Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738–44.CrossRefPubMed
23.
Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96(1):41–7.CrossRefPubMed
24.
Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010;115(12):2364–71.CrossRefPubMed
25.
Pepe A, Meloni A, Rossi G, Cuccia L, D’Ascola GD, Santodirocco M, et al. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy. J Cardiovasc Magn Reson. 2013;15:1.CrossRefPubMedPubMedCentral
26.
Pennell DJ, Carpenter JP, Roughton M, Cabantchik Z. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiovasc Magn Reson. 2011;13:45.CrossRefPubMedPubMedCentral
27.
28.
Ceci A, Mangiarini L, Felisi M, Bartoloni F, Ciancio A, Capra M, et al. The management of iron chelation therapy: preliminary data from a national registry of thalassaemic patients. Anemia. 2011;2011:435683.CrossRefPubMedPubMedCentral
29.
Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin. 2008;24(6):1609–21.CrossRefPubMed
30.
Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, et al. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells Mol Dis. 2010;45(2):136–9.CrossRefPubMed
31.
Luangasanatip N, Chaiyakunapruk N, Upakdee N, Wong P. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study. Clin Drug Investig. 2011;31(7):493–505.CrossRefPubMed
32.
Bentley A, Gillard S, Spino M, Connelly J, Tricta F. Cost-utility analysis of deferiprone for the treatment of beta-thalassaemia patients with chronic iron overload: a UK perspective. Pharmacoeconomics. 2013;31(9):807–22.CrossRefPubMedPubMedCentral
33.
34.
Capri S, Ceci A, Terranova L, Merlo F, Mantovani L, TMotIG P. Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Inform J. 2001;35:189–201.
35.
Russo P. Pharmacoeconomic evaluations in the Italian regulatory context: a qualiquantitative analysis of pricing and reimbursement dossiers. Pharmacoecon Ital Res Artic. 2008;10:59–75.CrossRef
36.
Karnon J, Tolley K, Vieira J, Chandiwana D. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective. Clin Drug Investig. 2012;32(12):805–15.CrossRefPubMed
37.
Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian society for thalassemia and hemoglobinopathies. Blood Cells Mol Dis. 2009;42(3):247–51.CrossRefPubMed
38.
Pepe A, Meloni A, Rossi G, Dell’Amico MC, Spasiano A, Capra M, et al. A T2* MRI prospective survey on heart iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy. J Cardiovasc Magn Reson. 2011;13(1):1–2. doi:10.​1186/​1532-429x-13-s1-o21.CrossRef
39.
Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455–62.CrossRefPubMed
40.
Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91(7):873–80.PubMed
41.
42.
Pepe A, Meloni A, Rossi G, Carollo A, Santamaria V, Scaccetti A, et al. Direct cost analysis about the three chelators for the treatment of thalassemia patients with chronic iron overload: an Italian perspective from the MIOT network. Blood. 2013;122(21):5605.
43.
Scalone L, Mantovani LG, Krol M, Rofail D, Ravera S, Bisconte MG, et al. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin. 2008;24(7):1905–17.CrossRefPubMed
44.
Young KE, Urbinati D, Toumi M. HTA, approach in Italy. Structure, methods, and process of veneto region’s evaluation of pharmaceutical effectiveness unit (Unità Di Valutazione Dell’efficacia Del Farmaco, Uvef). Value Health. 2014;17(7):A442–3.CrossRefPubMed
45.
Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17(5):479–500.CrossRefPubMed
46.
Briggs AH, Goeree R, Blackhouse G, O’Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22(4):290–308.CrossRefPubMed
47.
Xia S, Zhang W, Huang L, Jiang H. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. PLoS One. 2013;8(12):e82662.CrossRefPubMedPubMedCentral
Metadaten
Titel
Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective
verfasst von
Alessia Pepe
Giuseppe Rossi
Anthony Bentley
Maria Caterina Putti
Ludovica Frizziero
Domenico Giuseppe D’Ascola
Liana Cuccia
Anna Spasiano
Aldo Filosa
Vincenzo Caruso
Aishah Hanif
Antonella Meloni
Publikationsdatum
01.05.2017
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 5/2017
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-017-0496-1

Weitere Artikel der Ausgabe 5/2017

Clinical Drug Investigation 5/2017 Zur Ausgabe

Original Research Article

Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults

Original Research Article

Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings

Original Research Article

Effect of N-Acetylcysteine on Mortality and Liver Transplantation Rate in Non-Acetaminophen-Induced Acute Liver Failure: A Multicenter Study

Current Opinion

Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?

Original Research Article

Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States

Systematic Review

Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis